Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03937245
Registration number
NCT03937245
Ethics application status
Date submitted
1/05/2019
Date registered
3/05/2019
Titles & IDs
Public title
Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care
Query!
Scientific title
Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care: the Eurobact II Multinational Cohort Study
Query!
Secondary ID [1]
0
0
EurobactII
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EurobactII
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Bacteremia
0
0
Query!
Sepsis
0
0
Query!
Hospital Acquired Condition
0
0
Query!
Resistance Bacterial
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Observational [Patient Registry]
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
HA-BSI - Patients with HA-BSI treated in an ICU
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Mortality
Query!
Assessment method [1]
0
0
Vital status
Query!
Timepoint [1]
0
0
28 days
Query!
Secondary outcome [1]
0
0
Progress of organ failures
Query!
Assessment method [1]
0
0
Assessed by the components of the SOFA score
Query!
Timepoint [1]
0
0
7 days
Query!
Secondary outcome [2]
0
0
Days free or organ supportive therapy
Query!
Assessment method [2]
0
0
Days free of renal replacement therapy, mechanical ventilation, vasopressors, intensive care unit
Query!
Timepoint [2]
0
0
28 days
Query!
Secondary outcome [3]
0
0
Clinical cure
Query!
Assessment method [3]
0
0
As evaluated by the treating clinician
Query!
Timepoint [3]
0
0
7 days, 28 days
Query!
Secondary outcome [4]
0
0
Microbiological cure
Query!
Assessment method [4]
0
0
Presence of persisting or relapsing blood stream infection
Query!
Timepoint [4]
0
0
7 days, 28 days
Query!
Eligibility
Key inclusion criteria
* Age > 18 Years.
* Hospital Acquired Bloodstream Infection (HA-BSI).
* Treated in the ICU.
* ICU acquired OR
* Hospital acquired prior to ICU admission
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Patients that had a positive blood culture in the hospital and transferred to ICU for a different reason than specific treatment of the causes or consequences of HA-BSI.
* Previous inclusion in the study.
* HA-BSI is defined as a positive blood culture (BC) sampled after 48 hours following hospital admission.
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/08/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
3/06/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
3058
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
0
0
Redcliffe Hospital - Brisbane
Query!
Recruitment postcode(s) [1]
0
0
4020 - Brisbane
Query!
Recruitment outside Australia
Country [1]
0
0
France
Query!
State/province [1]
0
0
Paris
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Outcome Rea
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
European Society of Intensive Care Medicine
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
European Society of Clinical Microbiology and Infectious Diseases
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Government body
Query!
Name [3]
0
0
Institut National de la Santé Et de la Recherche Médicale, France
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Eurobact II will investigate the mortality and morbidity of hospital-acquired blood stream infections in patients treated in intensive care units (ICU). It will investigate the effects of the micro-organism and its characteristics, such as type and resistance to antibiotics on the infection and its consequences. It will also investigate the effects of the antibiotics and other treatments on survival of patients. Eurobact II will include patients from multiple ICUs in multiple countries.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03937245
Query!
Trial related presentations / publications
Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho F, Paiva JA, Cakar N, Ma X, Eggimann P, Antonelli M, Bonten MJ, Csomos A, Krueger WA, Mikstacki A, Lipman J, Depuydt P, Vesin A, Garrouste-Orgeas M, Zahar JR, Blot S, Carlet J, Brun-Buisson C, Martin C, Rello J, Dimopoulos G, Timsit JF. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012 Dec;38(12):1930-45. doi: 10.1007/s00134-012-2695-9. Epub 2012 Sep 26. Buetti N, Tabah A, Loiodice A, Ruckly S, Aslan AT, Montrucchio G, Cortegiani A, Saltoglu N, Kayaaslan B, Aksoy F, Murat A, Akdogan O, Saracoglu KT, Erdogan C, Leone M, Ferrer R, Paiva JA, Hayashi Y, Ramanan M, Conway Morris A, Barbier F, Timsit JF; Eurobact 2 study group. Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: a descriptive analysis of the Eurobact II study. Crit Care. 2022 Oct 18;26(1):319. doi: 10.1186/s13054-022-04166-y.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Alexis Tabah, MD
Query!
Address
0
0
ICU, Redcliffe Hospital, Faculty of Medicine, UQ, Brisbane, QLD, Australia.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/45/NCT03937245/Prot_SAP_000.pdf
Statistical analysis plan
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/45/NCT03937245/Prot_SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03937245